Patents by Inventor Monika Soukupova
Monika Soukupova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11397187Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.Type: GrantFiled: April 2, 2018Date of Patent: July 26, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Andrea Horsch, Birgit Klapperich, Dirk Block, Alfred Engel, Johann Karl, Rosemarie Kientsch-Engel, Ekaterina Manuilova, Christina Rabe, Sandra Rutz, Monika Soukupova, Ursula-Henrike Wienhues-Thelen, Peter Kastner, Edelgard Anna Kaiser
-
Patent number: 11372000Abstract: The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.Type: GrantFiled: August 13, 2019Date of Patent: June 28, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Klaus Hallermayer, Monika Soukupova, Christina Porzig, Ulrike Kurtkaya, Leopold Von Proff, Sonja Fiesel, Marion Herrmann, Stefanie Kern
-
Patent number: 10982007Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.Type: GrantFiled: March 21, 2017Date of Patent: April 20, 2021Assignee: Roche Diagnostics Operations, Inc.Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraeml, Monika Soukupova, Michael Tacke
-
Publication number: 20190369117Abstract: The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.Type: ApplicationFiled: August 13, 2019Publication date: December 5, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Klaus Hallermayer, Monika Soukupova, Christina Porzig, Ulrike Kurtkaya, Leopold Von Proff, Sonja Fiesel, Marion Herrmann, Stefanie Kern
-
Publication number: 20190137523Abstract: The present invention relates to a method for measuring the level of VEGF-A in the presence of a VEGF-A antagonist, kits comprising means for detecting VEGF-A in the presence of a VEGF-A antagonist, compositions of matter comprising a first and a second antibody suitable for detecting the level of VEGF-A in the presence of a VEGF-A antagonist, as well as methods of detecting a complex comprising human VEGF-A and a non-human or chimeric protein.Type: ApplicationFiled: January 10, 2019Publication date: May 9, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Alfred Engel, Johann Karl, Christina Rabe, Michael Schraeml, Monika Soukupova, Peter Stegmueller, Norbert Wild
-
Patent number: 10179815Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.Type: GrantFiled: March 29, 2016Date of Patent: January 15, 2019Assignees: VENTANA MEDICAL SYSTEMS, INC., ROCHE MOLECULAR SYSTEMS, INC.Inventors: Monika Soukupova, Michael Schraeml, Birgit Bossenmaier, Patrick C. Roche, Michael Gerg, Sebastian Dziadek
-
Publication number: 20180231570Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.Type: ApplicationFiled: April 2, 2018Publication date: August 16, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Andrea Horsch, Birgit Klapperich, Dirk Block, Alfred Engel, Johann Karl, Rosemarie Kientsch-Engel, Ekaterina Manuilova, Christina Rabe, Sandra Rutz, Monika Soukupova, Ursula-Henrike Wienhues-Thelen, Peter Kastner, Edelgard Anna Kaiser
-
Publication number: 20170275380Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10?3/sec to 10?4/sec, and the bivalent binding agent has a Kdiss of 3×10?5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.Type: ApplicationFiled: March 21, 2017Publication date: September 28, 2017Inventors: Michael Gerg, Dieter Heindl, Alfred Mertens, Christoph Rutz, Michael Schraemi, Monika Soukupova, Claudio Sustmann, Michael Tacke, Jan van Dieck
-
Publication number: 20170275381Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.Type: ApplicationFiled: March 21, 2017Publication date: September 28, 2017Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraemi, Monika Soukupova, Michael Tacke
-
Publication number: 20170096487Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.Type: ApplicationFiled: March 29, 2016Publication date: April 6, 2017Inventors: Monika Soukupova, Michael Schraeml, Birgit Bossenmaier, Patrick C. Roche, Michael Gerg, Sebastian Dziadek
-
Patent number: 9371509Abstract: The invention provides a composition containing an aqueous liquid phase, bacterial cells, and an ionic compound dissolved in the liquid phase. The ionic compound is selected from the group consisting of 1-butyl-3-methyl-imidazolium-thiocyanate, 1-butyl-3-methyl-imidazolium-2(2-methoxy-ethoxy)ethylsulfate, 1-methyl-1-[4-(3-methyl-3H-imidazol-1-ium)-but-1-yl]-3H-imidazolium-di(toluylsulfate), and 1-butyl-3-methyl-imidazolium-octylsulfate. The compositions of the invention are advantageously used for preparing lysates of biological cells, particularly bacterial cells.Type: GrantFiled: August 13, 2010Date of Patent: June 21, 2016Assignee: Roche Diagnostics Operations, Inc.Inventors: Christian Birkner, Herbert von der Eltz, Monika Soukupova
-
Publication number: 20150355199Abstract: The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto.Type: ApplicationFiled: August 26, 2015Publication date: December 10, 2015Inventors: Alfred Engel, Andreas Gallusser, Johann Karl, Peter Kastner, Wolfgang Obermeier, Monika Soukupova
-
Publication number: 20130288267Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10?3/sec to 10?4/sec, and the bivalent binding agent has a Kdiss of 3×10?5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.Type: ApplicationFiled: June 21, 2013Publication date: October 31, 2013Applicant: Roche Diagnostics Operations, Inc.Inventors: Michael Gerg, Dieter Heindl, Alfred Mertens, Christoph Rutz, Michael Schraeml, Monika Soukupova, Claudio Sustmann, Michael Tacke, Jan van Dieck
-
Publication number: 20130288266Abstract: A bi-valent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bi-valent binding agent, and for use of the disclosed bi-valent binding agent in histological staining procedures.Type: ApplicationFiled: June 21, 2013Publication date: October 31, 2013Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraeml, Monika Soukupova, Michael Tacke
-
Publication number: 20110053251Abstract: The invention provides a composition containing an aqueous liquid phase, bacterial cells, and an ionic compound dissolved in the liquid phase. The ionic compound is selected from the group consisting of 1-butyl-3-methyl-imidazolium-thiocyanate, 1-butyl-3-methyl-imidazolium-2(2-methoxy-ethoxy)ethylsulfate, 1-methyl-1-[4-(3-methyl-3H-imidazol-1-ium)-but-1-yl]-3H-imidazolium-di(toluylsulfate), and 1-butyl-3-methyl-imidazolium-octylsulfate. The compositions of the invention are advantageously used for preparing lysates of biological cells, particularly bacterial cells.Type: ApplicationFiled: August 13, 2010Publication date: March 3, 2011Inventors: Christian Birkner, Herbert von der Eltz, Monika Soukupova